A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults

Launched by PFIZER · May 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called PF-07999415 to understand how safe it is and how it works in the body. The researchers are looking for healthy adults aged 18 to 65 who do not have any serious health issues to participate. To join, participants should have a body weight over 110 pounds and a Body Mass Index (BMI) between 18 and 33. People with certain medical conditions or recent health issues may not be eligible.

Participants in the study will receive a single dose of PF-07999415 through a shot in their thigh, abdomen, or arm. After receiving the medicine, they will stay in a hospital-like setting for two weeks to be closely monitored for any reactions. The entire study will last between three to seven months, during which participants will return for follow-up visits every two weeks after their initial stay. This trial is important as it will help researchers determine if PF-07999415 is safe for future use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female participants of non-childbearing potential aged 18 to 65 years, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
• • Body Mass Index (BMI) of 18-33 kg/m2 and a total body weight \>50 kg (110 lb).
• Exclusion Criteria:
• • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, dermatological, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• • Previous administration of an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.